June 9, 2019Open Access

An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes

Key Points

Key points are not available for this paper at this time.

Abstract

Teplizumab delayed progression to clinical type 1 diabetes in high-risk participants. (Funded by the National Institutes of Health and others; ClinicalTrials.gov number, NCT01030861.).

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Kevan C. Herold

Brian N. Bundy

S. Alice Long

Journals

New England Journal of Medicine

Actions

Institutions

Yale University

University of Toronto

University of California, San Francisco

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study